Last reviewed · How we verify
Atony of uterus — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Pabal | CARBETOCIN | Ferring Pharmaceuticals Ltd | carbetocin | Oxytocin receptor | ||
| Duratocin | Duratocin | Dongyu Wang | Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V2 receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Dongyu Wang · 1 drug in Atony of uterus
- Ferring Pharmaceuticals Ltd · 1 drug in Atony of uterus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Atony of uterus:
- Atony of uterus treatment updates — RSS
- Atony of uterus treatment updates — Atom
- Atony of uterus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Atony of uterus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/atony-of-uterus. Accessed 2026-06-10.
Related
- Atony of uterus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing